
|Videos|September 9, 2017
Dr. Luke Discusses the Combination of Epacadostat and Pembrolizumab in Melanoma
Author(s)Jason J. Luke, MD
Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses the combination of epacadostat and pembrolizumab (Keytruda) for the treatment of melanoma during the 2017 ESMO Annual Congress.
Advertisement
Advertisement
Related Content
Advertisement



mRNA Vaccine Plus Pembrolizumab Yields RFS, DMFS Benefit in Melanoma
Published: | Updated:


Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Switching From Chemoimmunotherapy When a ROS1 Result Returns
2
Building an Adequate ROS1 Workup With RNA-Based Sequencing
3
Etentamig Improves Response, Survival in Phase 3 Trial for Relapsed/Refractory Myeloma
4
Ivonescimab Bests Pembrolizumab on Overall Survival in PD-L1+ NSCLC
5






























